Drug Information

Drug (ID: DG01854) and It's Reported Resistant Information

• Name: Teprotumumab
• Synonyms: Teprotumumab
• Indication:
  In total 2 Indication(s)
  Graves disease [ICD-11: 5A02]; Approved; [1]
  Diabetic macular edema [ICD-11: 9B71]; Investigative; [1]
• Target: Insulin-like growth factor I receptor (IGF1R); IGF1R_HUMAN; [1]
• DrugBank ID: DB06343

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Ewing sarcoma [ICD-11: 2B52]

Drug Sensitivity Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Protein-tyrosine phosphatase delta (PTPRD) [1]

• Sensitive Disease: Ewing sarcoma [ICD-11: 2B52.0]
• Molecule Alteration: Missense mutation; p.V253I (c.757G>A)
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Ewing sarcoma tissue; N.A.
• Experiment for Molecule Alteration: DNA sequencing assay
• Mechanism Description: The missense mutation p.V253I (c.757G>A) in gene PTPRD cause the sensitivity of Teprotumumab by unusual activation of pro-survival pathway

References

• Ref 1: Germline PTPRD mutations in Ewing sarcoma: biologic and clinical implicationsOncotarget. 2013 Jun;4(6):884-9. doi: 10.18632/oncotarget.1021.